Glioblastoma multiforme (GBM) is the most aggressive and the commonest primary brain tumor with a tendency for local invasiveness. The pathways of neoplasia, invasion and inflammation are inextricably linked in cancer and aberrations in several regulatory pathways for these processes have been identified. Here we have studied the FAT1 (Homo sapiens FAT tumor-suppressor homolog 1 (Drosophila)) gene to identify its role in the tumorigenecity of the gliomas. The expression of FAT1 was found to be high in grade IV glioma cell lines (U87MG, A172, U373MG and T98G) but low in grade III glioma cell lines (GOS3 and SW1088). Two cell lines (U87MG and A172) with high FAT1 expression were chosen for in vitro FAT1-knockdown studies. FAT1 knockdown by small interfering RNA resulted in decreased migration and invasion of both the cell lines along with increased expression of the tumorsuppressor gene programmed cell death 4 (PDCD4). Increased PDCD4 expression led to the attenuation of activator protein-1 (AP-1) transcription by inhibiting c-Jun phosphorylation and resulted in concomitant decrease in the expression of AP-1-target genes like MMP3, VEGF-C and PLAU, the pro-inflammatory regulator COX-2 and cytokines IL1b and IL-6. Conversely, simultaneous silencing of PDCD4 and FAT1 in these cells significantly enhanced AP-1 activity and expression of its target genes, resulting in increase in mediators of inflammation and in enhanced migratory and invasive properties of the cells. We also observed a negative correlation between the expression of FAT1 and PDCD4 (P ¼ 0.0145), a positive correlation between the expression of FAT1 and COX-2 (P ¼ 0.048) and a similar positive trend between FAT1 and IL-6 expression in 35 primary human GBM samples studied. Taken together, this study identifies a novel signaling mechanism mediated by FAT1 in regulating the activity of PDCD4 and thereby the key transcription factor AP-1, which then affects known mediators of neoplasia and inflammation.
INTRODUCTION
The signaling pathways propagated from the cell surface, through transmembrane receptors, to intracellular regulatory molecules are critical for maintaining cellular homeostasis. Knowledge of how these transmembrane proteins regulate the terminal components of the signaling pathway is crucial for understanding normal as well as aberrant cellular function. The link between cancer and inflammation is well established and a set of common molecules (for example, COX-2, IL-1b, IL-6 and so on) may mediate both the processes. [1] [2] [3] [4] [5] Various molecular pathways that promote tumor invasion and expression of pro-inflammatory molecules in cancer have been identified 6, 7 but many more are yet to be explored.
Glioblastoma multiformes (GBMs) are the most frequent and most malignant form of brain tumors. 8, 9 Tumor angiogenesis, invasiveness and rapid growth go in concert in GBM. [10] [11] [12] The tumor microenvironment exhibits expression of pro-inflammatory molecules that promote migration and invasion of tumor cells. 13, 14 There is increasing evidence of the role of the pro-inflammatory molecules in making glioma and other tumors more aggressive and resistant to chemo-and/or radio-therapy. [15] [16] [17] The common pathways may promote tumor invasiveness and expression of pro-inflammatory molecules in GBM. 13, 18 Of these, COX-2 and cytokines like IL-1b and IL-6 are the known mediators of both the processes. 19, 20 However, the therapeutic translation of this knowledge has been limited. 21 Here we have studied the role of FAT1, a transmembrane protein, in linking the neoplastic phenotype and inflammatory mediators in glial cells and have corroborated some of the results in primary human tumors.
FAT1 is a member of cadherin superfamily 22, 23 and was first identified as a tumor suppressor in Drosophila melanogaster, acting via the Salvador-Warts-Hippo signaling pathway. [24] [25] [26] [27] [28] [29] [30] There are contrasting studies about the role of FAT1 in human cancers, and its precise role in development and progression of human cancer is still being investigated.
Available literature on FAT1 in human cancers points toward its dual role, both as an oncogene as well as tumor suppressor. Overexpression of FAT1 has been reported in invasive breast carcinoma 31 and leukemia, 32 and loss of FAT1 has been reported to inhibit migration and invasion in OSCC, 33 indicating the oncogenic role of FAT1 in these tumors. However, tumors like oral cancer 34 and Mayer-Rokitansky-Kü ster-Hauser (MRKH) syndrome 35 have shown deletion/loss-of-heterozygosity of the chromosomal region 4q35 harboring FAT1 gene, suggesting its tumor-suppressor role. An initial report from our laboratory on FAT1 in glioma 36 had shown high loss-of-heterozygosity and low mRNA expression in 33% of the tumors studied and suggested that it may have a tumor-suppressor role. However, the signaling cascades and cellular processes through which FAT1 acts in different contexts are still being elucidated and very few functional studies are available on the role of FAT1 in human cancers, including GBM.
Programmed cell death 4 (PDCD4) is a known tumor-suppressor gene and it has an essential role in many biological processes like regulating cap-dependent translation, apoptosis, modulating various signal transduction pathways and so on. [37] [38] [39] The expression of PDCD4 is often decreased in human glioma 40 and many other progressive tumors like lung, breast 41, 42 and so on, leading to increased invasiveness and metastasis. [43] [44] [45] In addition, PDCD4 is also reported to suppress induction of inflammatory mediators. 46, 47 PDCD4 is known to inhibit activator protein-1 (AP-1)-mediated transcription, [48] [49] [50] which has a central role in multiple processes involved in tumorigenesis, including proliferation, migration and invasion, [51] [52] [53] [54] [55] [56] [57] and AP-1 inhibition had been shown to have anti-invasive and anti-growth effect. 58, 59 In order to elucidate the role of FAT1 in human glioma, we studied its expression in several glioma cell lines followed by knockdown in two GBM cell lines (U87MG and A172) with high FAT1 expression. There was a marked reduction in cell motility and invasiveness, as well as upregulation of PDCD4 expression. This in turn reduced AP-1 transcriptional activity, thus affecting transcription of downstream genes, including extra cellular matrix (ECM)-remodeling molecules (MMP3, PLAU and VEGF-C) and pro-inflammatory markers (COX-2, IL1b and IL-6). This process was reversed by simultaneous knockdown of FAT1 and PDCD4, thus validating the link between FAT1 and PDCD4 in regulating cellular motility, invasiveness and inflammatory microenvironment in glioma. These in vitro findings were further supported by the inverse relationship observed between mRNA levels of FAT1 and PDCD4 and a positive correlation between the transcript levels of FAT1 and COX-2, as well as of FAT1 and IL-6 in primary human GBM. Thus, this study identifies a novel function of FAT1 in regulating AP-1-mediated transcription via PDCD4.
RESULTS

FAT1
knockdown reduces migration and invasion of glioma cells FAT1 mRNA expression was checked in a panel of glioma cell lines and high FAT1 expression was observed in grade IV glioma (GBM) cell lines (U87MG, A172, U373MG and T98G) as compared with grade III glioma cell lines (GOS3 and SW1088) (Figure 1a ). The cell lines U87MG and A172 were studied further to analyze the effect of FAT1 knockdown. Knockdown efficiency of FAT1 in cells was checked by using a set of three FAT1-specific small interfering RNA (siRNA) (details in Materials and methods section) from Invitrogen (Carlsbad, CA, USA), and FAT1 siRNA I (HSS176716) was found to have maximum knockdown efficiency (Supplementary Figure S1) . FAT1 siRNA I was used for further experiments. We found X90% knockdown of FAT1 mRNA expression in FAT1 siRNA-treated cells (U87MGsiFAT1 and A172siFAT1) as compared with control siRNAtreated cells (siControl; Invitrogen), 72 h post transfection (Figure 1b ). There were significant morphological alterations (cells were more spindly) in siFAT1-treated cells (Figure 1c) .
We observed significant reduction in migration (about 50% decrease in U87MGsiFAT1 (Po0.01) and about 75% decrease in A172siFAT1 cells (Po0.001)) (Figure 1d ) as well as invasion (about 60% decrease in U87MGsiFAT1 and about 40% decrease in A172siFAT1 cells (Po0.01)) (Figure 1e ) upon FAT1 knockdown as compared with siControl cells. There was no variation in the distribution of cell population in different phases of cell cycle, as assessed by fluorescence-activated cell sorting analysis (Supplementary Figure S2a ), as well as in cell viability as assessed by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Supplementary Figure S2b) , after FAT1 knockdown. Further, there was no DNA fragmentation (4',6-diamidino-2-phenylindole staining) and no cleaved caspase-3 (western blot) after 72 h of transfection (Supplementary Figures S2c and d) , indicating that FAT1 knockdown did not affect cell viability and apoptosis.
FAT1 knockdown enhances PDCD4 expression
In initial screening by microarray (unpublished data) to study altered gene expression after FAT1 knockdown in U87MG cell line, we identified PDCD4 as one of the upregulated genes. This was further confirmed by quantitative PCR (q-PCR) and western blot analysis in four GBM cell lines, U87MG, A172, U373MG and T98G. There was significant (Po0.05) upregulation of about 2.4, 2.8, 3.2 and 3.5 fold in PDCD4 mRNA expression (Figure 2a ) as well as in PDCD4 protein expression (Figure 2b ) in siFAT1-treated U87MG, A172, U373MG and T98G cells, respectively, as compared with their respective siControl-treated cells. The grade III glioma cell line, GOS3, with low endogenous FAT1 expression ( Figure 1a ) had high PDCD4 mRNA expression (Figure 2c ), corroborating the inverse relationship between FAT1 and PDCD4.
In literature, phospho-Akt and PDCD4 are known to negatively regulate each others expression. 37, 60, 61 However, we observed increased phospho-Akt levels (Supplementary Figure S3) along with increased PDCD4 expression (Figures 2a, b ) after FAT1 knockdown in U87MG cells, suggesting that increased PDCD4 expression after FAT1 knockdown was independent of the p-Akt pathway.
FAT1 knockdown diminishes AP-1-mediated transcription PDCD4 is reported to inhibit AP-1-dependent transcription 48, 62 via suppression of c-Jun phosphorylation. 49, 50 Because c-Jun phosphorylation is required for AP-1 activity, we investigated the effect of FAT1 knockdown on c-Jun phosphorylation status by western blotting and found to be significantly decreased along with reduction in the total c-Jun protein level in U87MGsiFAT1 cells as compared with siControl cells (Figure 3a) . The c-jun mRNA level, as checked by q-PCR, was also found to be markedly decreased (0.51±0.12, Po0.01) in U87MGsiFAT1 cells as compared with U87MGsiControl cells (Figure 3b ). This could be due to decreased positive autoregulatory loop of c-jun transcription by AP-1. 63, 64 Hence, the reduction in the total c-Jun protein level in U87MGsiFAT1 cells may be due to both reduction in the c-jun mRNA level and ubiquitination and fast degradation of unphosphorylated c-Jun. 50, 65, 66 However, the exact mechanisms leading to decrease in p-c-Jun levels need to be elucidated further.
Further, we performed AP-1 luciferase assay to examine whether the upregulation of PDCD4 and diminished c-Jun phosphorylation in siFAT1 cells has any effect on AP-1 activity. We observed about 60% reduction (40.6±1.2, Po0.01) in AP-1 luciferase activity in U87MGsiFAT1 cells as compared with U87siControl cells (Figure 3c ). Moreover the mRNA expression of AP-1-target genes like MMP3, VEGF-C and PLAU (urokinase) were found to be decreased by 490% (Supplementary Figure S4a) , as well as ECM protease activity was found to be decreased in U87MGsiFAT1 cells as compared with siControl cells (Supplementary Figure S4b) . To further corroborate that PDCD4 regulates the AP-1-dependent transcription, PDCD4 expression was knocked down by using siPDCD4 in U87MG cells, and we observed about 1.5-fold increase (157±5.4, Po0.05) in AP-1 luciferase activity (Figure 3d ). Thus, confirming that increased PDCD4 expression after FAT1 knockdown attenuates AP-1 transcriptional activity via reduction in the level of phosphorylated c-Jun.
Knockdown of FAT1 decreases the expression of COX-2 and other cytokines COX-2 is known to be negatively regulated by PDCD4, 62, 67 and aberrant induction of COX-2 with upregulation of prostaglandin FAT1 gene in cancer and inflammation B Dikshit et al synthesis is reported to have a pivotal role in carcinogenesis. 68 COX-2 expression at mRNA and protein level was analyzed by q-PCR and western blotting. We found significant reduction of COX-2 expression at both mRNA (0.04±0.002, Po0.05) (Figure 4a ) and at protein level (Figure 4b ) in U87MGsiFAT1 cells as compared with siControl cells. The enzymatic product of COX-2, prostaglandin E 2 (PGE2), has a key role in influencing tumor progression. 69 The concentration of PGE2 secreted into the medium was found to be reduced by about 60% in U87MGsiFAT1 cells as compared with siControl cells (42±2.6, Po0.01) (Figure 4c ). Thus, this result depicts inhibition of COX-2 function leading to diminished PGE2 synthesis after FAT1 knockdown.
COX-2 has also been reported to regulate endogenous cytokine production, and its inhibition markedly reduces the release of proinflammatory cytokines like IL-1b and IL-6. 70 We also observed significant reduction in mRNA expression of COX-2 along with IL-1b (0.12±0.09, Po0.05) and IL-6 (0.13±0.11, P 0.01) after FAT1 knockdown in U87MG cells (Figure 4a ), thus identifying a novel AP-1-mediated regulation of COX-2 transcription has been reported earlier. 71, 72 To investigate whether the regulation of COX-2 expression by FAT1 in U87MG cells is mediated via AP-1, we inhibited AP-1 activity by treating cells with specific smallmolecule inhibitor of AP-1, SR11302. On treating U87MG cells with increasing concentration of SR11302 (0.1-10 mM), a dosedependent decrease in COX-2 luciferase activity was observed, with a maximum inhibition of about 80% at the dose of 5 and 10 mM concentrations (Supplementary Figure S5) . We observed marked decrease in COX-2 luciferase activity after treatment of U87MG cells with FAT1 siRNA (Po0.01) or 10 mM SR11302 (Po0.05), as well as combined treatment with FAT1 siRNA and SR11302 (Po0.001), as compared with siControl þ DMSO-treated U87MG cells (Figure 4d ). We also observed significant reduction in mRNA expression of COX-2 (0.37 ± 0.09, Po0.01), IL1b (0.42 ± 0.08, Po0.01) and IL-6 (0.29±0.1, Po0.05) after 48 h of SR11302 treatment (Figure 4e ). Our results thus provide further supportive evidence that AP-1 is a key link in the regulation of expression of COX-2 and other cytokines.
Inhibition of PDCD4 reverses the effects of FAT1 knockdown in FAT1-attenuated cells To confirm that the demonstrated effects of FAT1 knockdown were indeed due to the upregulation of PDCD4, we cotransfected FAT1 and PDCD4 siRNA in U87MG cells and could satisfactorily knock down levels of both the genes simultaneously (Figure 5a ). Migration and invasion were found to be significantly restored (Po0.001) in U87MG cells after simultaneous knockdown of FAT1 and PDCD4 (Figures 5b, c) . Moreover, AP-1 luciferase activity (Po0.01), as well as the mRNA expression of AP-1-target genes, was found to be significantly regained with simultaneous knockdown of FAT1 and PDCD4 as compared with U87MG cells treated with siFAT1 alone (Figure 5d ). At protein level, high PDCD4 expression observed after FAT1 knockdown was found to be decreased after simultaneous knockdown of FAT1 and PDCD4. However, the expression of p-c-Jun, VEGF-C and COX-2 was regained after simultaneous knockdown of PDCD4 and FAT1 as compared with cells treated with siFAT1 alone (Figure 5f ). We also observed low expression of AP-1-regulated transcripts in GOS3 cell Figure S6) , which has low FAT1 and high PDCD4 expression (Figure 2c ). Together, these results confirm the role of PDCD4 in mediating the observed effects of FAT1.
FAT1 and PDCD4 expression is inversely correlated in primary GBM samples PDCD4 expression is reported to be lost in human glioma and may contribute to the development of tumor. 40, 73 To study the relationship between FAT1 and PDCD4 expression in tumors, we checked the mRNA expression of both FAT1 and PDCD4 in 35 GBM samples by q-PCR (Table 1 ). The 35 GBM samples were arranged according to decreasing FAT1 expression and divided into quartiles. 74 The PDCD4 expression (mean value ± s.d.) in the first quartile (group A) with the highest FAT1 expression (0.586±0.998) was significantly less than that in the fourth quartile (group D) with the lowest FAT1 expression (54.108 ± 51.18), with P ¼ 0.0145. The inverse relationship observed between the expression of FAT1 and PDCD4 in tumor samples supports the in vitro results.
Further, we also analyzed the mRNA expression of COX-2 and IL-6 in these GBM samples and observed positive correlation with FAT1 expression. The COX-2 expression in group A (4.99±4.074) was significantly higher as compared with group D (0.248±0.174) with P ¼ 0.048. The IL-6 expression in groups A (13.6±25.69) and D (1.21 ± 2.97) was found to follow a similar trend, however, it was not statistically significant (P ¼ 0.146).
DISCUSSION
The role of FAT1 as an apical regulator of the Salvador-WartsHippo pathway and its function as a tumor-suppressor gene is well documented in Drosophila 24,28 but there are limited reports regarding the role of FAT1 in human cancers. A study from our laboratory 36 had shown extensive variation in FAT1 expression with 33% of glioma samples having low FAT1 mRNA expression and loss-of-heterozygosity at FAT1 locus in a significant number of the glioma samples studied. Another study 34 had showed homozygous deletion of FAT1 gene and low expression in oral carcinoma. Role of FAT1 had also been suggested in development of fallopian tube cancer in patients of MRKH syndrome. 35 In contrast, high FAT1 expression has been reported in breast cancer 31 and leukemia where it is considered as an independent prognostic marker. 32 The role of FAT1 in cell migration is also well studied [75] [76] [77] [78] and its knockdown has been reported to inhibit migration of VSMC 79 and OSCC cells. 33 The signaling cascade being regulated by FAT1 gene and the function of FAT1 gene in human cancers including GBM is not Here we investigated the functional role of FAT1 by analyzing its expression in glioma cell lines followed by siRNA knockdown of FAT1 in cells with high FAT1 expression. We observed high FAT1 mRNA expression in grade IV glioma cell lines like U87MG, A172, U373MG and T98G and decreased expression in grade III glioma cell lines (GOS3 and SW1088). Knockdown of FAT1 in U87MG and A172 led to marked reduction in migratory and invasive properties of the cells along with high expression of PDCD4. Increased PDCD4 expression was also observed upon FAT1 knockdown in U373MG and T98 cell lines. PDCD4 is known to inhibit migration and invasion in various cancers like breast, ovarian, colon and so on. 49, 82 Loss of PDCD4 expression has been linked with cell proliferation and unfavorable prognosis in gliomas. 40, 73, 83 Decreased migration and invasion observed in U87MG and A172 cell lines after FAT1 knockdown in this study might be attributed to increased PDCD4 expression. High PDCD4 expression after FAT1 knockdown was not found to induce apoptosis or alter cell-cycle distribution in both U87MG and A172 cell lines, which is in accordance to a similar study in NIH3T3 cells by Shibahara et al. 84 but in contrast to report on breast cancer cell lines. 85 This difference can be due to molecular cross-talk between different signaling cascades in cell lines affecting the functioning of the cells in a context-dependent manner. In our study, we observed that high PDCD4 levels after FAT1 knockdown mainly regulate migration and invasion in glioma cells. Decreased PDCD4 is known to have an important role in tumor progression [86] [87] [88] and in remodeling ECM during invasion. 89, 90 To further confirm the link between FAT1 and PDCD4, we simultaneously knocked down PDCD4 and FAT1 expression and found reversal of migratory and invasive properties of the cells, which further confirmed that the observed effects of FAT1 knockdown are mainly mediated by PDCD4.
Because PDCD4 is known to attenuate AP-1-mediated transcription by inhibiting c-Jun phosphorylation, 49, 50 we checked the effect of FAT1 knockdown on the AP-1 activity by luciferase assay and observed diminished AP-1 transcriptional activity and decreased expression of AP-1-regulated transcripts like ECMremodeling molecules MMP3, VEGF-C, PLAU, inflammatory mediator COX-2 and cytokines IL1b and IL-6. Overexpression of pro-inflammatory molecules in GBM and their role in glioma progression is well known. 13 Moreover, the role of various signaling molecules in promoting inflammatory response in gliomas has also been convincingly demonstrated. 18, 20, 91, 92 The reduced AP-1 activity observed in glioma cell lines after FAT1 knockdown could be attributed to inhibition of c-jun transcription and c-Jun phosphorylation by increased PDCD4 expression. These effects were further confirmed by dual knockdown of FAT1 and PDCD4 in both U87MG and A172 cell lines. Also, the increased PDCD4 expression after FAT1 knockdown in glioma cells was found to be independent of the Akt pathway. The observation of FAT1 in regulating PDCD4 expression and its downstream effect on tumor migration and invasion is a novel finding with implications for glioma biology.
We have shown that FAT1 is linked to COX-2 via PDCD4 and AP-1. The downregulation of COX-2 expression and pro-inflammatory cytokines via PDCD4 upregulation after FAT1 knockdown has considerable significance in the regulation of inflammatory responses in glioma. Decreased COX-2 expression after FAT1 knockdown led to reduced PGE2 production and decreased mRNA expression of IL-6 and IL-1b, thus providing a crucial link between tumor progression and inflammation. COX-2 expression is known to be regulated by AP-1 binding to cyclic adenosine monophosphate response element in the COX-2 promoter. 71 We have shown that inhibition of AP-1 by SR11302 led to significant reduction in COX-2 promoter luciferase activity as well as mRNA expression of the AP-1-regulated genes COX-2, IL-6 and IL-1b. The role of PDCD4 in downregulating COX-2 is known 62, 67 and suppression of PDCD4 is found to increase invasive activity of COX-2 in breast cancer cells. 82 COX-2 overexpression is also reported in high-grade gliomas [93] [94] [95] and many other tumors with potential for targeting it as anti-cancer modality. 69, 70, [96] [97] [98] [99] [100] Our finding of reduced COX-2 expression and decreased synthesis of To further validate the in vitro findings about the relationship between FAT1 and PDCD4, we studied the expression of FAT1 and PDCD4 in 35 primary GBM samples by q-PCR and found a statistically significant inverse correlation between the two. Further, we also observed a positive correlation between FAT1 and COX-2 expression and a similar trend for IL-6 expression in GBM samples studied. These findings further support the in vitro results about the inverse relationship between FAT1 and PDCD4 and their influence on the expression of AP-1-mediated transcripts like COX-2, IL-6 and so on.
We therefore demonstrate for the first time that FAT1 has an important role in modulating PDCD4 expression, which in turn regulates AP-1-dependent transcription, controlling processes crucial for migration and invasion in glioma cells, as well as the induction of a pro-inflammatory microenvironment in glioma. The study illustrates a link between inflammation and cancer in glioma and raises the possibility that FAT1 might be a master regulator in this process. This work highlights the importance of FAT1 in the induction of the cellular pathways of migration and invasion, proteolysis of the ECM and the expression of pro-inflammatory molecules leading to a favorable microenvironment for tumor progression. The possible signaling pathway being regulated by FAT1 is shown in Figure 6 and has been illustrated in a set of glioma cell lines with corroborative evidence from primary human GBM. Till now, targeting pro-inflammatory molecules or the related pathways as therapeutic strategies to prevent or treat cancers has had a limited success and there is considerable interest in focusing on such molecules. 101, 102 The transmembrane molecule, FAT1, thus promises to be one such novel target for therapeutic intervention in cancer and inflammation as well as the link between the two processes.
MATERIALS AND METHODS
Reagents and antibodies
Set of three siRNAs for FAT1 knockdown, FAT Stealth RNAi siRNA-I(HSS103567) FAT Stealth RNAi siRNA-II(HSS103568) and FAT Stealth RNAi siRNA-III(HSS176716) and universal medium GC control siRNA (cat.
no.12935-112) were purchased from Invitrogen Life technologies (Grand Island, NY, USA). For simultaneous knockdown, on-target plus siRNA against FAT1(J-010513-07-0020) and PDCD4(J-004438-08-0020) and ontarget plus non-targeting pool(D-001810-10-20) as control siRNA from Dharmacon (Lafayette, CO, USA). AP-1 luciferase reporter plasmid (AP-1 7 Â ) was purchased from Stratagene, and COX-2 promoter luciferase construct was a kind gift from Dr Miguel A Iniguez,Centro de Biología Molecular Universidad Autó noma de Madrid, Spain. AP-1 inhibitor SR11302 was purchased from Tocris Biosciences (Bristol, UK). 103 Normal brain RNA was procured from Ambion (Austin, TX, USA), Life Technologies (Carlsbad, CA, USA) and Clontech (Mountain view, CA, USA). Antibodies used for western blots, like PDCD4, COX-2, p-c-Jun, c-Jun and b-actin were from Cell Signaling Technology (Beverly, MA, USA), VEGF and Caspase-3 were from Abcam (Cambridge, UK). Primers were designed using Primer3 software and ordered from MWG Biotech (Ebersberg, Germany).
Cell culture and siRNA transfection
The human glioma cell lines U87MG, U373, A172, T98G, GOS3 and SW1088 were obtained from ATCC (Rockville, MD, USA) cultured in Dulbecco's Modified Eagle Medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10%(v/v) fetal calf serum (Sigma-Aldrich), 3.7 g/l sodium bicarbonate (Sigma-Aldrich), ciprofloxacin 10mg/ml and 5%CO 2 at 37 1C. cDNA synthesis and q-PCR Total RNA was isolated from cells at appropriate time point using TRIzol reagent (Invitrogen), quantified using a Nanodrop ND-1000 spectrophotometer. DNase(Ambion) treatment was given and 1 mg of total RNA was used for cDNA synthesis, done by Fermentas RevertAid First Strand cDNA Synthesis Kit using random decamers. PCR reactions were carried in 10-ml reaction volumes (2.5 ml of 1:5 diluted cDNA, 0.5 ml of primer mix, 1 ml of 10 Â Taq Buffer-A, 0.5 U Taq polymerase (Bangalore-Genei, Bangalore, India), 1 ml Syto9(Invitrogen), 0.25 ml of 10mM dNTPs (MBI-Fermentas; Thermo Fisher Scientific, Rockford, IL, USA) and 4.6 ml of NFW (Ambion)) on a RotorGene6000 Real-Time PCR Corbett Life Science (Mortlake, NSW, Australia) in triplicates. The detail of the primers used is given in Supplementary Table S1 . DC t values were defined as target gene C t minus 18 S RNA C t and averaged for each triplicate sample. Statistical significance was determined by Student's t-test analysis (Po0.05).
Western blotting analyses
Cells were lysed in triple detergent buffer containing protease and phosphatase inhibitors (Sigma-Aldrich), lysates were quantified by BCA kit (Pierce, Thermo Fisher Scientific, Rockford, IL, USA) and electrophoresed in 10% SDS-PAGE and electroblotted on nitrocellulose membrane (Millipore, Billerica, MA, USA). Membrane was blocked with 5% bovine serum albumin in 1 Â Tris-buffered saline at 4 1C O/N. Primary and secondary antibodies were diluted in 5% bovine serum albumin and 0.1% tween-20 in 1 Â Tris-buffered saline. Blot was incubated in primary antibody overnight at 4 1C followed by secondary antibody incubation for 2 h at room temperature. Blot was developed by BCIP-NBT (Promega, Madison, WI, USA) and captured using Alpha Imager EP software (Alpha Innotech Corp, San Leandro, CA, USA).
Migration and invasion assays
The modified Boyden chamber/matrigel assay was performed according to the manufacturer's directions (BD Biosciences, Bedford, MA, USA). For in vitro migration assays, we used chambers with control inserts that lacked the matrigel coating. Transfections were carried out in U87MG and A172 cells and 48 h later 3 Â 10 4 U87MG cells per well and 7 Â 10 4 A172 cells per well were resuspended in serum-free Dulbecco's Modified Eagle Medium and seeded in triplicate in matrigel-coated (1 mg/ml; BD Biosciences) and uncoated control inserts (8-mm-pore-size, BD Biosciences). The remaining protocol was done as previously described. 42 AP-1 and COX-2 promoter luciferase assay U87MG cells (40 000 cells per well) were plated in six-well plates in triplicate. On day 1, cells were transfected with siFAT1/siPDCD4 and siControl. On day 2, cells were transiently transfected with 7 Â AP-1 luciferase reporter plasmids as described previously. 49, 62 Cells were transfected with 1 mg of AP-1 7 Â luciferase reporter plasmid, along with 50 ng of pRL-TK (Renilla luciferase) control plasmid using Lipofectamine-2000 as the transfection reagent. After 48 h, the cells were lysed by 1 Â passive lysis buffer (Promega) and assayed for luciferase activity as previously described. 49 For COX-2 luciferase assay, U87MG cells were transfected with siFAT1 and siControl on day 1 and after 4 h incubation were treated with 10 mM SR11302. On day 2, cells were transiently transfected with COX-2 reporter plasmid 104 and again treated with 10 mM SR11302. After 48 h, the cells were assayed for luciferase activity. 
Statistical analysis
All in vitro experiments were performed in triplicate and repeated thrice. q-PCR for patient tumor samples were performed in triplicate. Differences were determined using Student's t-test, and Po0.05 was considered significant. Data are shown as the mean±s.d.
